Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...
Main Authors: | Jeffrey Vietri, James Harnett, Birol Emir, Erica Chilson |
---|---|
格式: | Article |
語言: | English |
出版: |
Taylor & Francis Group
2020-01-01
|
叢編: | Human Vaccines & Immunotherapeutics |
主題: | |
在線閱讀: | http://dx.doi.org/10.1080/21645515.2019.1632683 |
相似書籍
-
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
由: Strutton David R, et al.
出版: (2012-08-01) -
EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
由: M. V. Fedoseenko, et al.
出版: (2014-09-01) -
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
由: Germaine Hanquet, et al.
出版: (2022-01-01) -
Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
由: John M. McLaughlin, et al.
出版: (2019-04-01) -
Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
由: Hyunju Lee, et al.
出版: (2014-02-01)